
Isabl
Cancer tests based on whole genome and transcriptome data.
Monthly revenue–Not shared yet
Rank–Unranked
Last 30 days–Growth in MRR
Revenue per founder–– founders
About Isabl
Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.
Discover more startups
Browse the board →MRR
$251K
Last 30 days
-2%
Founder
Jacob Jacquet
MRR
$250K
Last 30 days
0%
Founder
Eugene Zolotarenko
MRR
$250K
Last 30 days
0%
Founder
Valon Asani